Droperidol effective for antiemetic prophylaxis in morphine-based intravenous patient-controlled analgesia

Results

After matching, 1,104 subjects were included for analysis. The addition of droperidol to IV-PCA reduced the risk of PONV (aOR: 0.49, 95% CI: 0.35–0.67, p < 0.0001). The antiemetic effect of droperidol was significant within 36 h after surgery and attenuated thereafter. Droperidol was significantly associated with a lower risk of antiemetic uses (aOR: 0.58, 95% CI: 0.41–0.80, p = 0.0011). The rate of unintentional sedation was comparable between the patients with (9.1%) and without (7.8%; p = 0.4481) the addition of droperidol. Postoperative opioid consumption and numeric rating scale acute pain scores were similar between groups.

The addition of droperidol to IV-PCA reduced the risk of PONV without increasing opiate consumption or influencing the level of sedation. However, additional prophylactic therapies are needed to prevent late-onset PONV.

Reference:

Tan, J.Q., Wu, HL., Wang, YC. et al. Antiemetic prophylaxis with droperidol in morphine-based intravenous patient-controlled analgesia: a propensity score matched cohort study. BMC Anesthesiol 23, 351 (2023). https://doi.org/10.1186/s12871-023-02319-2

Keywords:

Droperidol, effective, antiemetic, prophylaxis, morphine-based, intravenous, patient-controlled, analgesia, BMC Anesthesiology, Tan, J.Q., Wu, HL., Wang, Y